Michael Thurn

Part of Gilead Sciences, Inc., YM BioSciences Australia Pty Ltd. develops cancer treatment pharmaceuticals. The company is based in Melbourne, Australia.

Xenome Ltd. discovered and developed peptide pharmaceuticals. Its product, Xen2174, was a novel conopeptide analogue for the treatment of severe pain. The company was founded in 2008 and was headquartered in Indooroopilly, Australia.

Mimetica Pty Ltd. is a holding company, which engages in the development of products for the treatment of acne. It has a drug discovery platform technology based on the rational design of small molecules that mimic natural peptide hormones. The company was founded in 2001 and is headquartered in Southbank, Australia.

Spinifex Pharmaceuticals Pty Ltd. discovers and develops new drugs for the treatment and management of pain. The firm conducts medicinal chemistry and drug discovery activities, preclinical and early-phase clinical studies before seeking a partnership with pharmaceutical company to complete clinical development, file for regulatory approval, and carry out marketing activities. The company was founded in June 2005 and is headquartered in Preston, Australia.